IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline
Retrieved on:
星期二, 三月 12, 2024
Other Health, Technology, Pharmaceutical, Mental Health, Infectious Diseases, Neurology, Artificial Intelligence, Clinical Trials, Other Technology, Science, Biotechnology, Alternative Medicine, Other Science, Health, Research, NCI, Agitation, Patient, Committee, National Cancer Institute, Virology, University, Quality of life, NIH, House, Myenteric plexus, Pancreatic Cancer Action Network, University of Maryland, Baltimore, Fetal alcohol spectrum disorder, IGC, IHV, Pharma, Jan Vansina, Bangladesh Technical Education Board, Therapy, Senate, Dementia, Public affairs, Pharmaceutical industry
IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) today announced that it has appointed Terry Lierman as an independent director to its board of directors.
Key Points:
- IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) today announced that it has appointed Terry Lierman as an independent director to its board of directors.
- Terry founded the Children’s Research Institute, one of America's top children’s research programs, the Pancreatic Cancer Action Network (PanCAN), and the National Organization on Fetal Alcohol Syndrome (NOFAS).
- Ram Mukunda, CEO of IGC Pharma, commented, “With his track record of execution and extensive experience in health care, Mr. Lierman will undoubtedly bring invaluable insights and strategic guidance to IGC Pharma.
- I look forward to collaborating with the talented team at IGC Pharma to drive forward the mission of bringing transformative therapies to patients in need.”